Development of an intraoral device for therapeutic drug monitoring of anti-epileptic drugs

NIH RePORTER · NIH · R21 · $205,084 · view on reporter.nih.gov ↗

Abstract

PROJECT ABSTRACT Saliva is the ideal biofluid for therapeutic drug monitoring applications in general, and specifically for continuous monitoring because it is amenable to measurement noninvasively within the oral cavity. The development of an intraoral device for the continuous real-time monitoring of anti-epileptic drugs in saliva could enable the promise of precision medicine and advancing optimal dosing for each individual. In this project, we will demonstrate feasibility of our proposed intraoral sensor platform by coupling capillarity-based microfluidics and electrochemical detection to ultra-low-power readout electronics, and to use a machine-learning-based approach for offline processing of sensor data, to create an intraoral sensor for the real-time quantification of therapeutic drug levels in saliva in the presence of variation of salivary pH, temperature, and other common confounders. The intraoral sensor will consist of a reusable, comfortable electronics module that will fit securely into the patient’s mouth, and that interfaces with a disposable microfluidic chip containing voltammetry-based detection. The intraoral sensor electronics module will communicate wirelessly with a mobile device that will process the data and display and relay drug levels semi-continuously and in real time.

Key facts

NIH application ID
10452435
Project number
1R21DE031101-01A1
Recipient
OREGON STATE UNIVERSITY
Principal Investigator
Elain Fu
Activity code
R21
Funding institute
NIH
Fiscal year
2022
Award amount
$205,084
Award type
1
Project period
2022-04-14 → 2024-03-31